drugset

drugset / Trial / NCT01635023

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

NCT01635023 ↗

Phase 1 Completed 27 enrolled AstraZeneca

RandomizedCrossoverOpen-labelBasic science

Summary

Study in Healthy Males to Compare the White and Blue Formulations of AZD6244.

Timeline

Start: 2012-07
Primary completion: 2012-10
Completion: 2012-10

Publications

Tomkinson H, McBride E, Martin P, Lisbon E, Dymond AW, Cantarini M, So K, Holt D. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects. Clin Ther. 2017 Nov;39(11):2260-2275.e1. doi: 10.1016/j.clinthera.2017.08.022. Epub 2017 Oct 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selumetinib	Small molecule	35 mg	Oral
Subject	Selumetinib	Small molecule	75 mg	Oral

Indications

No indication recorded.